Figure 7.
(a) Inhibition of LTB4 plus PGE2-stimulated PMN infiltration in mouse outer ears by topical administration (20 μg per ear) of ZK-994, and ZK-142. Values are expressed as the % inhibition of ear myeloperoxidase activity in vehicle-treated mice that received LTB4 plus PGE2 (6.2±2.7 mAU min−1 per biopsy). Values are means±s.e.m., n=4 (* significantly different from vehicle, P⩽0.05; # significant differences among treatment groups, P⩽0.05). (b) Ear biopsies: inhibition of dermal inflammation. Sagittal sections of the mouse outer ear were stained with haematoxylin/eosin (magnification × 40). The representative photographs show ear sections with hair follicles and sebaceous glands. Left panel; LTB4 plus PGE2-stimulated inflammation. Note the prominent papillary dermal vascularity (large arrow), minute intraepithelial abscess (small arrow), and diffuse neutrophilic infiltrate (dashed circles). Right panel; inhibition of neutrophil infiltration by topical administration of compound ZK-142 (20 μg per ear) 5 min prior to LTB4 plus PGE2. (c) Photographs of mouse ears: inhibition of PMN-mediated vascular leakage in mouse outer ears by topical administration of ZK-994, and ZK-142 (20 μg per ear). (d) Inhibition of LTB4 plus PGE2-stimulated vascular leakage in mouse outer ear at 7 and 20 h after topical administration (20 μg per ear) of ATLa2, ZK-994, and ZK-142. Values are expressed as the % inhibition of Evans blue accumulation in ears of vehicle-treated mice that received LTB4 plus PGE2 (19.3±6.1 and 51.6±23.5 mAU min−1 per biopsy, at 7 and 20 h, respectively). Values are mean±s.e.m., n=3–5 (* significantly different from ATLa2 and ZK-142 at 7 h; P<0.05).